Quarterly Result4 Feb 2026, 05:02 pm
Dishman Carbogen Amcis Ltd Reports Q3 & 9MFY26 Net Revenue Growth
AI Summary
Dishman Carbogen Amcis Ltd, a fully integrated CDMO company, announces their Q3 & 9MFY26 results with a 5.5% increase in Q3 net revenue and a 4.3% increase in 9MFY26 net revenue. The growth is mainly due to higher revenue from the CDMO segment and increased Cholesterol and Vitamin D analogues revenue contribution. EBITDA Margin is at 15.7% in Q3FY26 and 19.4% in 9MFY26.
Key Highlights
- Net Revenue at Rs.7,198 mn in Q3FY26 up by 5.5% as compared to Rs. 6,823 mn in Q3FY25 mainly due to higher revenue from CDMO segment.
- Net Revenue at Rs.20,805 mn in 9MFY26 up by 4.3% as compared to Rs. 19,952 mn in 9MFY25 mainly due to higher Cholesterol and Vitamin D analogues revenue contribution.
- CDMO revenue for Q3FY26 is higher by 6.7% compared to Q3FY25 and marginally higher by 1.6% YoY in 9MFY26 primarily due to higher development revenue.
- Marketable Molecules (MM) segment revenue for Q3FY26 decreased by 2.4% as compared to Q3FY25 primarily due to lower Quats revenue and MM revenue increased by 21.5% in 9MFY26 mainly due to increase in Cholesterol and Vitamin D analogues supplies.
- EBIDTA Margin at 15.7% in Q3FY26 compared to 20.5% in Q3FY25 mainly due to decrease in margins in CDMO and MM segments.